Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review

Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial

(2020) Sanne Y. Smith-Apeldoorn et al.   BMC Psychiatry

Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies

(2020) Wei Zheng et al.   JOURNAL OF AFFECTIVE DISORDERS

The influence of ketamine’s repeated treatment on brain topology does not suggest an antidepressant efficacy

(2020) Natalia Gass et al.   Translational Psychiatry

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data

(2020) Michel Nijs et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

(2020) Dawn F Ionescu et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis

(2020) Jiaqi Xiong et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

(2019) Vanina Popova et al.   AMERICAN JOURNAL OF PSYCHIATRY

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

(2019) Jean Kim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Esketamine for treatment resistant depression

(2019) Jennifer Swainson et al.   Expert Review of Neurotherapeutics

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

(2019) Maggie Fedgchin et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

(2019) Kenji Hashimoto   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression

(2019) Ella J. Daly et al.   JAMA Psychiatry

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3

(2019) Rachel Ochs-Ross et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential

(2019) Rupert McShane et al.   AMERICAN JOURNAL OF PSYCHIATRY

Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials

(2019) Katrina Witt et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study

(2018) Carla M. Canuso et al.   AMERICAN JOURNAL OF PSYCHIATRY

The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses

(2018) Myrela O. Machado et al.   BMC Medicine

Mechanisms of ketamine action as an antidepressant

(2018) P Zanos et al.   MOLECULAR PSYCHIATRY

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

(2018) Panos Zanos et al.   PHARMACOLOGICAL REVIEWS

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression

(2018) Ella J. Daly et al.   JAMA Psychiatry

Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis

(2017) Francesco Bartoli et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder

(2016) Brittany Jaso et al.   Current Neuropharmacology

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

The use of ketamine as an antidepressant: a systematic review and meta-analysis

(2015) Caoimhe M. Coyle et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review

(2014) Gianluca Serafini et al.   Current Neuropharmacology

Are antidepressants equally effective in the long-term treatment of major depressive disorder?

(2014) Massimiliano Buoli et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development

(2011) Xiaohua Li et al.   NEUROPSYCHOPHARMACOLOGY

Intravenous Augmentative Citalopram Versus Clomipramine in Partial/Nonresponder Depressed Patients

(2009) Alfredo Carlo Altamura et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Glutamate-based antidepressants: 20 years on

(2009) Phil Skolnick et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

The molecular neurobiology of depression

(2008) Vaishnav Krishnan et al.   NATURE